A method for constructing a mouse model of urosepsis
By using a micro-infusion pump to continuously infuse the bladder with urinary pathogenic Escherichia coli solution, the problem of existing sepsis models being unable to simulate the pathophysiological chain of urinary sepsis was solved, enabling a minimally invasive, parameterized, and highly reproducible mouse model of urinary sepsis.
Patent Information
- Application Number
- CN202611383530.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-08
- Publication Date
- 2026-11-17
AI Technical Summary
Existing sepsis models cannot effectively simulate the pathophysiological chain of urinary sepsis, especially the progression from the urinary tract infection to systemic infection. Furthermore, they are complex to operate or require the implantation of foreign bodies, making it difficult to standardize and replicate the parameters.
A micro-infusion pump was used to continuously infuse urinary pathogenic Escherichia coli solution into the bladder through a catheter under pressure. The insertion depth, flow rate, total volume, and time were controlled to simulate the upward development of urinary tract infection and its entry into the bloodstream, resulting in systemic dissemination.
This method enables the stable reproduction of the pathological features of urosepsis, including bladder overload, kidney involvement, bacterial entry into the bloodstream, and dissemination to distant organs, under minimally invasive conditions, thus improving the accuracy and reproducibility of the model.
Smart Images

Figure CN123100563A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of animal model construction technology for sepsis, and in particular to a method for constructing a mouse model of urinary sepsis. Background Technology
[0002] Urosecoma is a severe infectious state that develops from a urinary tract infection and causes systemic reactions and organ dysfunction. Its clinical course usually has a clear source of urinary tract infection and may be accompanied by upper urinary tract involvement, bacteremia, bacterial dissemination to distant organs, and acute kidney injury. The core pathological feature is a progressive course of ascending urinary tract infection → pyelonephritis → kidney injury → systemic sepsis. Therefore, establishing an animal model that can preserve the origin of urinary tract infection and stably produce a systemic infection phenotype is an important foundation for studying the pathogenesis of urosecoma and evaluating intervention measures.
[0003] Existing sepsis models each have their applicable scope. The cecal ligation and puncture (CLP) model mainly simulates peritoneal multibacterial infections and is not suitable for urinary sepsis. Intravenous injection of live bacteria can rapidly induce bacteremia, but the bacteria directly enter the circulation, lacking a urinary tract infection origin, and cannot simulate the pathophysiological chain of "urinary tract infection focus → bacterial entry into the bloodstream → systemic inflammatory response" in clinical urinary sepsis. Conventional retrograde inoculation via the urethra and bladder can simulate urinary tract infection relatively well, but under certain conditions it mainly leads to local infection of the bladder or kidney, progressing to systemic infection. The extent and speed of infection development are affected by factors such as inoculation volume, urination, and catheter position, making it impossible to develop into a systemic infection. Furthermore, it cannot simulate the high-pressure bacterial entry process caused by urinary tract procedures (such as retrograde angiography and bladder irrigation) in clinical urinary sepsis. The bladder foreign body implantation model can form a persistent infection, but because it requires the insertion of a catheter patch, it introduces a foreign body reaction, making it closer to the specific clinical scenario of catheter-associated urinary tract infection than general urinary sepsis. Moreover, its operation requires precise insertion of the catheter patch, which is technically demanding and has limited throughput.
[0004] For example, Rittirsch et al. published the classic CLP model; studies on urinary tract pathogenic Escherichia coli CFT073 infection via the urethra have disclosed routine urinary tract infection modeling methods; Pathogens 2023 reported a high-throughput urinary sepsis model with implanted bladder foreign bodies. These methods provide a foundation for research in this field, but further improvements are still needed in areas such as "preserving the source of urinary tract infection," "avoiding laparotomy or foreign body implantation," "rapidly generating systemic dissemination," and "improving reproducibility through defined operational parameters."
[0005] Therefore, there is a need to establish a method for constructing a mouse model with a clear operational path, standardized parameters, adjustable infection severity, and the ability to establish a model of kidney involvement and systemic bacterial dissemination while preserving the source of urinary tract infection. Summary of the Invention
[0006] The purpose of this invention is to address the above-mentioned problems by providing a method for constructing a mouse model of urosepsis.
[0007] The first aspect of this invention provides a method for constructing a mouse model of urosepsis, employing the following technical solution:
[0008] A method for constructing a mouse model of urosepsis includes the following steps:
[0009] S1. Select mice and fix them in a supine position under anesthesia and warming conditions;
[0010] S2. Prepare a bacterial suspension of pathogenic Escherichia coli in the urinary tract and adjust the bacterial suspension concentration;
[0011] S3. Insert the catheter into the mouse bladder through the urethra, controlling the insertion depth to be 7-9 mm;
[0012] S4. Place the bacterial solution prepared in S2 into a micro-injection pump, set the flow rate and total volume, and continuously pressurize the bladder to infuse the bacterial solution within a predetermined time. After infusion, stop the anesthesia and revive the mouse under warm conditions. After the mouse regains its righting reflex, return it to its rearing environment. The continuous pressurization refers to using a micro-injection pump to drive the liquid through a catheter into the bladder at a constant flow rate, forming a continuous infusion pressure and flow environment, which promotes the bacteria to develop upward along the urinary tract and enter the blood circulation.
[0013] Preferably, the mice are 6-8 week old, SPF-grade female C57BL / 6J mice weighing 18-22 g.
[0014] Preferably, the urinary tract pathogenic Escherichia coli is UPEC CFT073; the bacterial suspension is prepared by inoculating the seed culture into LB medium, culturing to the logarithmic growth phase, collecting the bacterial cells by centrifugation, washing with sterile PBS, and resuspending.
[0015] Preferably, the bacterial concentration is adjustable within a range of 1×10⁻⁶. 7 ~1×10 9 The severity of the model can be adjusted by changing the bacterial concentration (CFU / mL).
[0016] Preferably, the bacterial solution concentration is 1×10⁻⁶. 8 CFU / mL.
[0017] Preferably, the conduit is made of PE10 polyethylene and the cut length is approximately 10 mm.
[0018] Preferably, in step S3, before catheter insertion, air in the catheter loop needs to be purged and a sterile lubricant needs to be applied to the outer wall of the catheter for lubrication.
[0019] Preferably, in step S3, the total pumping volume is 1 mL, the flow rate is 3 mL / h, and the duration is 20 min.
[0020] Preferably, after construction, the successful construction of the model is evaluated by monitoring at least one of the following: changes in mouse body temperature, bacterial load in blood and distant organs (spleen, liver, heart), serum creatinine and urea nitrogen levels, and renal tissue pathological damage indicators.
[0021] A second aspect of the present invention provides the application of the mouse model of urosepsis constructed by the above-described construction method in the rescreening or evaluation of drugs for the treatment of urosepsis.
[0022] In summary, this application includes at least one of the following beneficial technical effects:
[0023] 1. By employing a pump-driven pressurized instillation method via retrograde bladder instillation through the urethra, a certain concentration of pathogenic Escherichia coli bacterial solution is continuously pumped into the bladder through a catheter. By standardizing the bacterial solution concentration, total volume, flow rate, duration, and catheter depth, a continuous instillation environment is created within the bladder, thereby promoting the upward development of infection along the urinary tract and, under suitable conditions, leading to bacteremia, dissemination to distant organs, and kidney damage. The bacteria enter the bladder via the urethra, preserving the source of urinary tract infection. This simulates the high-pressure bacterial entry process caused by urinary tract procedures (such as retrograde angiography, bladder instillation, etc.) in clinical urinary sepsis, improving the accuracy of the model.
[0024] 2. The construction method provided in this application is minimally invasive, requiring no laparotomy, ureteral ligation, or bladder foreign body implantation, thus reducing the interference of additional surgery and foreign body reactions on the infection phenotype.
[0025] 3. By precisely controlling key physical parameters to regulate the model phenotype, the parameterized design enables the model to stably reproduce the typical pathological features of urosepsis, namely "high bladder load - kidney involvement - bacterial entry into the bloodstream - dissemination to distant organs", thereby improving the success rate of experiments. Attached Figure Description
[0026] Figure 1 A schematic diagram illustrating the operational flow of the construction method provided in this application. Figure 1 A, B, C, and D represent the steps of mouse fixation, tubing preparation, transurethral catheterization, and continuous infusion via a microinfusion pump, respectively.
[0027] Figure 2 This is a representative HE staining image of kidney tissue from the uninfected control group and the standard parameter pressurized perfusion group in Example 2;
[0028] Figure 3 This is a comparison chart of renal tissue damage scores between the uninfected control group and the standard parameter pressurized perfusion group in Example 2;
[0029] Figure 4 This is a 7-day survival curve of the pressurized perfusion model with different bacterial concentrations in Example 3;
[0030] Figure 5 The figure shows the experimental results of IR-61 near-infrared fluorescence tracing.
[0031] Figure 6 Survival curves for different modeling methods at 7 days;
[0032] Figure 7 Curves showing body temperature changes from 0 to 48 hours after modeling using different modeling methods;
[0033] Figure 8 This is a graph showing the bacterial load comparison results 24 hours after modeling. Figure 8 A, B, C, and D are comparative graphs of bacterial load in blood, spleen, kidney, and bladder, respectively.
[0034] Figure 9 Representative images of HE staining of kidney tissue 24 h after different modeling methods;
[0035] Figure 10 Comparison of renal tissue damage scores using different modeling methods;
[0036] Figure 11 Serum creatinine levels 24 h after modeling using different methods;
[0037] Figure 12 Serum urea nitrogen levels 24 h after modeling using different methods. Detailed Implementation
[0038] To make the objectives, technical solutions, and advantages of this invention clearer, the invention will be further described in detail below with reference to embodiments and accompanying drawings. It should be understood that the specific embodiments described herein are merely illustrative and not intended to limit the invention. Modifications or equivalent substitutions made by those skilled in the art based on their understanding of the technical solutions of this invention, without departing from the spirit and scope of the invention, should all be covered within the protection scope of this invention.
[0039] Unless otherwise specified, the reagents, instruments and equipment used in the following examples are all commercially available products. Other experimental operating conditions not specified shall be performed according to standard conditions or the manufacturer's recommendations.
[0040] I. Implementation Examples
[0041] Example 1
[0042] This embodiment provides a method for constructing a mouse model of urosepsis, including the following steps:
[0043] S1. Select mice and fix them in a supine position under anesthesia and warming conditions;
[0044] S2. Prepare a bacterial suspension of pathogenic Escherichia coli in the urinary tract and adjust the bacterial suspension concentration;
[0045] S3. Insert the catheter into the mouse bladder through the urethra, controlling the insertion depth to be 7-9 mm;
[0046] S4. Place the bacterial solution prepared in S2 into a microinfusion pump, set the flow rate and total pump volume, and continuously pressurize and infuse the bladder to ensure that the bacterial solution is pumped within a predetermined time. After infusion, stop anesthesia and resuscitate the mouse under warm conditions. After the mouse regains its righting reflex, return it to its rearing environment. The continuous pressurization infusion refers to using a microinfusion pump to drive the liquid through a catheter into the bladder at a constant flow rate, forming a continuous infusion pressure and flow environment, which promotes the bacteria to develop upward along the urinary tract and enter the blood circulation. In the following description, "transurethral bladder pressurization infusion model" also refers to the urosepsis mouse model provided in this application.
[0047] Reference Figure 1 The specific operating steps are as follows:
[0048] 1. Laboratory animals, equipment and reagents
[0049] Experimental animals: SPF-grade female C57BL / 6J mice, 6-8 weeks old, weighing 18-22g, were purchased from the Experimental Animal Center of the Army Characteristic Medical Center of Army Medical University, with production license number SCXK (Yu) 2022-0011 and usage license number SYXK (Yu) 2022-0018. They were acclimatized for 7 days (temperature 22±2℃, humidity 50-60%, 12h light-dark cycle), and fasted for 4 hours before surgery but allowed free water.
[0050] Strains: Uropathogenic Escherichia coli CFT073 (UPEC CFT073, stored at -80℃), purchased from Hangzhou Baosai Biotechnology Co., Ltd., strain number ATCC 700928;
[0051] Equipment and reagents: PE10 polyethylene catheter (inner diameter approximately 0.28 mm, outer diameter approximately 0.61 mm), syringe, disposable intravenous infusion needle, microinfusion pump, sterile liquid paraffin, LB culture medium, sterile PBS, isoflurane, and routine tissue sampling and testing equipment.
[0052] 2. Preparation and Counting Calibration of Bacterial Culture
[0053] UPEC CFT073 strain was scraped from cryovials stored at -80℃ and streaked onto LB agar plates, then incubated at 37℃ for 16–18 h. Single colonies were picked and inoculated into 5 mL of LB liquid medium, and cultured at 37℃ and 200 rpm with shaking for 12–16 h to obtain a seed culture (overnight seed culture, OD600 ≈ 1.5–2.0). The seed culture was then inoculated into fresh LB medium at a ratio of 1:50–1:100 and cultured at 37℃ and 200 rpm with shaking for 2.5–3.5 h until the early logarithmic growth phase (OD600 ≈ 1.5–2.0). =0.3~0.5), collect bacterial cells by centrifugation at 4℃ and 4000rpm for 10min, wash twice with sterile PBS and resuspend. Adjust the bacterial concentration initially based on OD600, and perform 10-fold serial dilutions and plate colony counting (take 50μL of bacterial solution for 10-fold serial dilution, take 20μL of each dilution and spread on LB agar plates, incubate at 37℃ for 16-18h, count, and calculate the actual CFU concentration). Calibrate to the target concentration using the actual CFU effect. In this example, the bacterial concentration was adjusted to 1.0×10⁻⁶. 8 CFU / mL.
[0054] 3. Anesthesia and positioning of mice
[0055] (1) Induction of anesthesia: Anesthesia was induced by 3% to 4% isoflurane combined with 1.0 to 1.5 L / min oxygen for 2 to 3 minutes until the righting reflex of the mouse disappeared.
[0056] (2) Maintenance anesthesia: Anesthesia is maintained with a mask, isoflurane concentration of 1.5% to 2.0%, and oxygen flow rate of 0.8 to 1.0 L / min.
[0057] (3) Keep warm: Place the mice on a constant temperature heating pad (37±0.5℃) to keep them warm.
[0058] (4) Position fixation: The mouse is placed in a supine position, its limbs are fixed, and its perineum is facing the operator.
[0059] (5) Criteria for depth of anesthesia: loss of pinch reflex, weakened corneal reflex, and stable breathing (60-80 breaths / min).
[0060] 4. Urethral catheterization and pressure irrigation
[0061] (1) Preoperative preparation: Take a 10 mL syringe and draw up the bacterial solution calibrated to the target concentration. Connect it to a disposable intravenous infusion needle. Cut the PE10 catheter to a length of about 10 mm. Use ophthalmic forceps to attach the PE10 catheter to the needle of the disposable intravenous infusion needle. Push the syringe handle to expel the air from the infusion set and the PE10 catheter. Apply a small amount of sterile liquid paraffin to the outer wall of the catheter for lubrication.
[0062] (2) Urethral catheterization: Clean the area around the mouse urethral opening and slowly insert the PE10 catheter into the mouse bladder through the urethral opening to a depth of 7-9 mm. When slight resistance is encountered and urine can be seen flowing back from the catheter, it is confirmed that the catheter has entered the bladder.
[0063] (3) Pressurized perfusion: Place the syringe containing the bacterial solution on the micro-injection pump and start perfusion at the set flow rate. In this embodiment, the bacterial solution concentration is 1×10⁻⁶. 8 The bacterial concentration was set at CFU / mL, with a total pumping volume of 1 mL, a flow rate of 3 mL / h, and continuous perfusion for 20 min. The concentration could be adjusted to 1×10⁻⁶ CFU / mL depending on experimental requirements. 7 ~1×10 9 The flow rate can be adjusted within the range of CFU / mL, the flow rate can be adjusted within the range of 1 to 10 mL / h, and the perfusion time can be adjusted within the range of 10 to 60 min.
[0064] Terminology Explanation: In this invention, "pressurized irrigation" refers to the continuous flow of fluid into the bladder via a catheter using a micro-infusion pump at a set flow rate, thereby creating continuous irrigation pressure and a flow environment. This invention uses flow rate, total pump volume, and duration as repeatable controllable operating parameters, and does not require a specific absolute intrabladder pressure value as a necessary limitation. The term "total irrigation volume" or "total pump volume" refers to the total amount of fluid output by the micro-infusion pump within a set time, and is not equivalent to the instantaneous volume remaining in the bladder cavity at any given time. A small amount of fluid may leak out through the urethral opening during continuous irrigation; this phenomenon does not change the definition of the pumping parameters.
[0065] 5. Postoperative recovery and observation
[0066] After perfusion, stop isoflurane and ventilate with pure oxygen for 1-2 minutes; place the mice in a 37°C constant temperature resuscitation chamber and keep them in a lateral position until the righting reflex is restored (about 5-10 minutes); fast for 2 hours after surgery but allow water, then resume normal feeding.
[0067] Observation time points: 0h, 6h, 12h, 24h, 48h, 72h, to record the clinical symptoms of sepsis and the survival status of mice.
[0068] 6. Model Evaluation Methods
[0069] Whether a model has been successfully established should be judged comprehensively based on the source of infection, whether bacteria enter the bloodstream or spread to distant organs, systemic clinical phenotypes, and organ damage. A single indicator should not be used as the sole criterion. Independent observation cohorts should be set up according to the experimental objectives. Non-terminal observation animals should be used for body temperature and survival experiments. Bacterial load, serum biochemistry, and pathological tests should be performed using endpoint sampling animals to avoid conflicts between endpoint sampling and long-term observation of the same animal.
[0070] (1) Clinical symptoms: mental state, activity level, piloerection, breathing, eye appearance, response to stimuli, etc.
[0071] (2) Bacterial load detection: Whole blood and required organs (liver, spleen, kidney, lung, bladder, etc.) were collected from mice under aseptic conditions. The organs were placed in homogenization tubes containing 1 mL of sterile PBS and homogenized in an ice bath using a tissue homogenizer until no obvious tissue clumps remained, preparing a tissue homogenate. The original sample solution and 10-fold serial dilutions (10...) were collected. -1 10 -2 20 μL of each sample was evenly spread onto LB agar plates and incubated at 37°C for 16–18 h before colony counting. Blood bacterial load was expressed as log10 CFU / mL, while spleen, kidneys, and bladder were expressed as log10 CFU / organ based on the whole organ diameter. Samples below the limit of detection (LLOD) were marked in the figure.
[0072] (3) Detection of inflammatory factors: After collecting whole blood, serum was separated and the levels of serum inflammatory factors (IL-6, TNF-α, IL-1β, IL-10, etc.) were detected by ELISA.
[0073] (4) Complete blood count test: A portion of whole blood was placed in a centrifuge tube containing EDTA anticoagulant and the white blood cell count (WBC), neutrophil percentage (NEUT%), platelet count (PLT) and other indicators were detected using a fully automated blood cell analyzer.
[0074] (5) Organ function test: Serum creatinine (Cr), blood urea nitrogen (BUN), alanine aminotransferase (ALT), aspartate aminotransferase (AST) and other indicators were detected by a biochemical analyzer.
[0075] (6) Histopathological examination: Kidney, liver, lung, and other tissues were collected 24 h after modeling, fixed in 4% paraformaldehyde for 24–48 h, routinely embedded in paraffin, sectioned to a thickness of 4–5 μm, stained with hematoxylin and eosin (HE), and observed under a light microscope. Renal tubular injury was assessed using a semi-quantitative scoring system of 0–5 points: 0 points, no obvious injury; 1 point, damaged renal tubules <10%; 2 points, 10%–25%; 3 points, 26%–50%; 4 points, 51%–75%; 5 points, >75%. The evaluation included renal tubular dilation, epithelial cell swelling or vacuolar degeneration, epithelial shedding, casts, and inflammatory cell infiltration.
[0076] The final determination of successful establishment of a urinary sepsis model requires the simultaneous fulfillment of the following conditions: at least two serum inflammatory factors are increased by more than 5 times compared with the control group; live bacteria are detected in the blood (>10 CFU / mL); bacterial load of at least two distant organs (liver, spleen, lung) is >100 CFU / g; and the pathological score of at least two organs ≥2 points on HE staining is required.
[0077] 7. The Humane End
[0078] Mice should be euthanized if they exhibit any of the following: persistent severe respiratory distress or cyanosis, inability to move or turn over independently, significant dehydration or inability to eat or drink, body temperature below 30°C for more than 2 hours, or weight loss exceeding 20% of their baseline body weight.
[0079] Example 2
[0080] This embodiment validates the urosepsis model constructed in Example 1.
[0081] Independent batches of female C57BL / 6J mice were used, with five mice in each group (uninfected control group and pressure-perfused model group). The model group used the standard parameters of this invention: bacterial concentration 1×10⁻⁶. 8 CFU / mL, total pump volume 1 mL, flow rate 3 mL / h, duration 20 min, insertion depth 7–9 mm; control group received no live bacteria and underwent corresponding sham treatment.
[0082] Approximately 3 hours after perfusion, the model group exhibited lethargy, and approximately 6 hours later, sepsis-like symptoms such as decreased activity and piloerection appeared. 24 hours after model establishment, viable bacteria were detected in blood cultures, and high bacterial loads were detected in the kidneys, bladder, and spleen.
[0083] Kidney tissue was taken for HE staining experiment, and the results are as follows: Figure 2 As shown (magnification 200x, scale bar = 100μm, 20× and 40× in the figure are objective lens magnifications), the renal tubular injury score comparison chart is as follows. Figure 3 As shown in the figure, the HE results indicate significant inflammatory cell infiltration and renal tubular epithelial damage, with the renal tubular damage score being higher than that of the uninfected control group.
[0084] Under the experimental conditions of this batch, all model animals met the preset comprehensive model phenotypic criteria, indicating that the mouse model of urinary sepsis was successfully constructed and that the above standard parameters had good reproducibility.
[0085] Example 3
[0086] This embodiment verifies the effect of bacterial concentration on the severity of a transurethral bladder pressurization perfusion model.
[0087] To evaluate the regulatory effect of bacterial concentration on the severity of the model, three dose groups were set up for comparison while keeping the perfusion volume, flow rate, duration and cannulation depth consistent.
[0088] Thirty independent female C57BL / 6J mice were randomly divided into three groups of 10 mice each. Each group received 1×10⁻⁶ mg of chlorine dioxide. 7 CFU / mL (low-dose group), 1×10 8CFU / mL (medium dose group) and 1×10 9 CFT073 bacterial suspension at CFU / mL (high-dose group). Except for the bacterial suspension concentration, all other pressurized perfusion parameters were kept consistent: total perfusion volume 1 mL, flow rate 3 mL / h, duration 20 min, and cannulation depth 7–9 mm. Patients were observed continuously for 7 days after model establishment, mortality was recorded, and Kaplan-Meier survival curves were plotted.
[0089] The results are as follows Figure 4 As shown in the figure, the overall mortality rate of the low-dose group was low, with a survival rate of about 80% on day 7; the survival rate of the medium-dose group gradually decreased, reaching about 60% on day 3 and stabilizing at about 50% from day 5 to 7; the high-dose group had the earliest mortality, with a mortality rate of about 70% on day 1, about 30% on day 2, about 20% on day 3, and about 10% from day 5 to 7.
[0090] The above results indicate that, under the condition that other perfusion parameters are consistent, the model mortality risk increases with increasing bacterial concentration, showing a clear dose-dependent trend. (1×10⁻⁶) 8 The CFU / mL group had a 7-day survival rate of approximately 50%, which not only resulted in a relatively obvious disease phenotype but also preserved a certain window for observation and intervention. Therefore, it was selected as the preferred bacterial concentration in the standard parameters of this application.
[0091] II. Comparative Example
[0092] Comparative Example 1
[0093] This comparative study compares the IR-61 near-infrared fluorescence tracer used in the transurethral bladder pressurization instillation method with that used in the conventional transurethral retrograde injection (UTI) method.
[0094] Using the near-infrared fluorescent tracer IR-61, the time characteristics of the distribution of intravesical fluid to the upper urinary tract and systemic tissues after two administration methods—hyperbaric instillation and conventional retrograde intravesical injection—were compared to verify the promoting effect of hyperbaric instillation on the upward urinary tract and systemic dissemination of intravesical substances.
[0095] 1. Laboratory animals and grouping
[0096] Sixteen female C57 mice were randomly divided into four groups: a routine transurethral retrograde injection + IR-61 group (n=5), a routine transurethral retrograde injection + PBS group (n=5), a pressurized instillation + IR-61 group (n=3), and a pressurized instillation + PBS group (n=3). For the routine injection groups, one animal was collected at 1, 4, 8, 12, and 24 hours. For the pressurized instillation groups, three animals were collected at 1 hour, with each group serving as an independent biological replicate.
[0097] 2. Preparation and administration of IR-6 working solution
[0098] IR-61 (CAS No. 1895075-34-9) was prepared with PBS. In the conventional transurethral retrograde vesicular injection group, a 1:50 (v / v) dilution was administered, with 50 μL of IR-61 working solution injected into the bladder per mouse via the urethra. In the pressurized perfusion group, a 1:500 (v / v) dilution was administered, with 500 μL continuously pumped at a rate of 3 mL / h for 10 min. The equivalent volume of IR-61 received by each mouse in both methods was approximately 1 μL to minimize bias caused by differences in the total amount of tracer. The corresponding PBS control group was treated with an equal volume of PBS administered via the same route.
[0099] 3. Material Sampling and Imaging
[0100] The endpoint was to collect bilateral kidneys and their connected upper urinary tract tissues, spleen, heart, liver, bladder and whole blood, and to image them using consistent scanning parameters on the Odyssey near-infrared fluorescence imaging system (scan resolution 169 μm, scan height 3.0 mm, image quality Medium).
[0101] 4. Results
[0102] The results are as follows Figure 5 As shown in the figure, after conventional retrograde injection via the urethra and bladder, IR-61 signals were mainly located in the bladder at 1 h; signals began to appear in the relevant areas of the upper urinary tract at 4 h; signals appeared in both kidneys and some distant tissues at 8 h; and varying degrees of fluorescence signals were observed in the kidneys, spleen, heart, liver, bladder, and blood at 12 h; and the signals in most tissues were significantly weakened at 24 h. In contrast, after pressurized perfusion, IR-61 signals were observed in both kidneys, blood, and tissues such as the liver, spleen, and heart, except for the bladder, only 1 h later. No corresponding IR-61 specific fluorescence signal was observed in the PBS control. During the perfusion process, a small amount of fluid was observed to leak from the urethral opening in some mice after a cumulative infusion of approximately 200 μL.
[0103] The above results indicate that, under conditions of equivalent IR-61 dosage, pump-driven pressurized perfusion resulted in earlier distribution of the tracer fluid in the upper urinary tract and distant tissues within the bladder. It should be noted that IR-61 is a small-molecule fluorescent tracer, and its in vivo behavior is not equivalent to that of live bacteria; this embodiment is only used to evaluate the distribution kinetics of the perfusion fluid, providing a basis for fluid distribution in subsequent live bacteria experiments.
[0104] Comparative Example 2
[0105] This comparative study compares the modeling effects of three methods: transurethral bladder pressurized instillation, conventional transurethral retrograde bladder injection, and tail vein injection. Under live bacterial conditions, the systemic disease phenotype, bacterial dissemination characteristics, and kidney damage of the three methods are systematically compared to evaluate the model characteristics of the construction method provided by this invention.
[0106] 1. Preparation of bacterial culture
[0107] In the comparative experiment of the three modeling methods, the concentration of CFT073 bacterial culture was uniformly adjusted to 1×10⁻⁶. 8 The bacterial culture concentration was CFU / mL, and the preparation method was the same as in Example 1, so it will not be repeated here.
[0108] 2. Animal grouping
[0109] Set up independent 24-hour endpoint sampling cohorts, 48-hour body temperature observation cohorts, and 7-day survival observation cohorts.
[0110] (1) 24-hour endpoint sampling cohort: The following groups were set up: uninfected control group, tail vein injection group, routine transurethral retrograde injection group (UTI group) and transurethral bladder pressure instillation group, with 5 animals in each group and a total of 20 animals.
[0111] (2) 48-hour body temperature observation cohort: Tail vein injection group, UTI group and pressurized perfusion group were set up, with 5 animals in each group and a total of 15 animals.
[0112] (3) 7-day survival observation cohort: There were four groups: uninfected control group, tail vein injection group, UTI group, and pressurized perfusion group, with 10 animals in each group, for a total of 40 animals. Animals that reached the preset humanitarian endpoint and were euthanized were included in the survival analysis by event.
[0113] 3. Modeling methods
[0114] (1) Tail vein injection group: The concentration of 1×10⁻⁶ was injected into the tail vein of mice. 8 150 μL of CFT073 bacterial culture with CFU / mL.
[0115] (2) Conventional transurethral retrograde vesicular injection group (UTI group): After anesthetizing mice, a catheter was inserted through the urethra, and a concentration of 1×10⁻⁶ was slowly injected into the bladder. 8 50 μL of CFT073 bacterial culture with CFU / mL was injected, and the catheter was removed after the injection was completed.
[0116] (3) Transurethral bladder pressurized instillation group: The procedure was performed according to the method provided in Example 1. After anesthetizing the mice, a catheter was inserted through the urethra (insertion depth 7-9 mm), and a microinfusion pump was connected for continuous instillation. The standard modeling parameters were: bacterial concentration 1×10⁻⁶. 8CFU / mL, total perfusion volume 1 mL, flow rate 3 mL / h, duration 20 min.
[0117] (4) Uninfected control group: No live bacteria were given, and a sham treatment matching the corresponding experiment was performed.
[0118] 4. Detection Method
[0119] Animals in the 24-hour endpoint sampling cohort were sacrificed 24 hours after modeling, and samples of blood, kidneys, spleen, and bladder were collected. Bacterial load, serum creatinine and urea nitrogen, and kidney tissue pathology were performed according to the method provided in Example 1.
[0120] Body temperature was measured in the 48-hour observation cohort before modeling and at 2, 4, 8, 12, 24, 36 and 48 hours after modeling.
[0121] After the 7-day survival observation cohort was established, the animals were continuously observed for 7 days. The time of death and survival status of each group of animals were recorded. The time of death or reaching the humane end point was continuously recorded and Kaplan-Meier curves were plotted.
[0122] 5. Results
[0123] 5.1 Survival Outcome
[0124] Survival curves Figure 6 As shown in the figure, during the 7-day observation period, the survival rate was 100% in the control group, approximately 90% in the UTI group, approximately 50% in the pressurized perfusion group, and approximately 30% in the tail vein injection group. This indicates that the conventional UTI model has a lower overall lethality, tail vein injection leads to faster systemic infection and a higher risk of death, while the disease severity in the pressurized perfusion group falls between the two.
[0125] 5.2 Changes in body temperature
[0126] Results of body temperature changes as follows Figure 7 As shown in the figure, the body temperature of all groups was close to 36 ℃ before modeling. In the tail vein injection group, the body temperature dropped rapidly after modeling, reaching its lowest value of approximately 33.8 ℃ after about 4 hours, and then gradually recovered. In the pressurized perfusion group, significant hypothermia appeared between 4 and 8 hours, reaching approximately 34.0 ℃ after about 8 hours, and then recovered, approaching 36 ℃ after 48 hours. The UTI group showed less temperature variation, generally maintaining a temperature of approximately 35.8–36.2 ℃ during the observation period. These results indicate that pressurized perfusion can induce a more significant systemic hypothermic response, with a different time course than direct tail vein infection.
[0127] 5.3 Bacterial colonization and systemic dissemination
[0128] Bacterial load comparison results as follows Figure 8 As shown, where, Figure 8Figures A, B, C, and D show the comparison results of bacterial load in blood, spleen, kidney, and bladder, respectively. As can be seen from the figures, 24 h after modeling, the bacterial load in blood was lowest in the UTI group, mainly around 1.5–2.5 log10 CFU / mL; approximately 3.1–3.9 log10 CFU / mL in the pressurized perfusion group; and highest in the tail vein injection group, approximately 4.0–4.6 log10 CFU / mL. The spleen showed a similar trend.
[0129] The bacterial load in the kidneys was highest in the pressurized perfusion group, reaching over 6 log10 CFU / kidneys; followed by the tail vein injection group, while the UTI group had a relatively lower load. In the bladder, the pressurized perfusion group had approximately 7 log10 CFU / bladder, the UTI group also maintained a high local load, while the tail vein injection group had the lowest load, with some samples approaching the detection limit.
[0130] Therefore, tail vein injection mainly manifests as high blood and spleen load, UTI group mainly manifests as local urinary tract infection, while pressurized perfusion group simultaneously exhibits high bladder / kidney load and blood / spleen dissemination, showing a distribution pattern of "urinary tract infection - kidney involvement - blood and distant organ dissemination".
[0131] 5.4 Renal histopathology and renal tubular injury score
[0132] HE staining results of different models are as follows Figure 9 As shown (magnification 200x, scale bar = 100μm, 20× and 40× in the figure are objective lens magnifications), the renal tissue damage score is as follows: Figure 10 As shown in the figure, HE staining revealed that the UTI group showed a certain degree of renal tubular lumen dilation, local inflammatory cell infiltration, and swelling / vacuolar changes of renal tubular epithelial cells; the tail vein injection group showed more obvious renal interstitial inflammatory cell infiltration and renal tubular epithelial damage; and the pressurized perfusion group showed more extensive inflammatory cell aggregation and infiltration, accompanied by renal tubular structural disorder, epithelial cell swelling, and vacuolar changes.
[0133] The renal tissue damage score was consistent with the histological observations above: the pressure perfusion group had the highest score, followed by the tail vein injection group, and the UTI group had the lowest score. This result is consistent with the higher renal bacterial load in the pressure perfusion group.
[0134] 5.5 Kidney function
[0135] The results of serum creatinine levels 24 h after modeling using different methods are as follows: Figure 11 As shown, the serum urea nitrogen levels 24 hours after modeling using different methods are as follows: Figure 12As shown in the figure, 24 h after modeling, the serum creatinine in the control group was approximately 40 μmol / L; in the UTI group, it was approximately 50 μmol / L; in the tail vein injection group, it was approximately 60 μmol / L; and in the pressurized perfusion group, the average was approximately 130–140 μmol / L, with some animals approaching 300 μmol / L.
[0136] The changes in serum urea nitrogen followed the same trend as creatinine: approximately 7–8 mmol / L in the control group, approximately 10–11 mmol / L in the UTI group, approximately 14 mmol / L in the tail vein injection group, and an average of approximately 24–25 mmol / L in the pressurized perfusion group, with some animals exceeding 30 mmol / L. Combined with the results of renal CFU and HE, this indicates that the pressurized perfusion model resulted in significant infection-related renal function impairment at 24 h.
[0137] Based on survival, body temperature, tissue bacterial load, kidney pathology, and kidney function results, conventional UTI models mainly retain the local urinary tract infection phenotype; tail vein injection can lead to rapid bacteremia and a high mortality rate, but lacks the origin of urinary tract infection; transurethral bladder pressurized instillation simultaneously shows high bacterial load in the bladder and kidneys, bacterial entry into the bloodstream, and dissemination to distant organs, accompanied by hypothermia, renal tubular damage, and abnormal kidney function, better reflecting the model characteristics of the progression from urinary tract infection to systemic infection.
[0138] The following methods were used for processing and statistical analysis of all experimental data in this application: GraphPad Prism software was used for statistical analysis and plotting. Quantitative data were expressed as mean ± standard deviation (mean ± SD) or median (interquartiles) according to their distribution. For data that conformed to a normal distribution and had homogeneous variances, one-way ANOVA was used for comparisons among multiple groups, followed by Tukey multiple comparisons; for data that did not conform to a normal distribution or homogeneity of variance, the Kruskal–Wallis test was used, followed by Dunn multiple comparisons.
[0139] Body temperature data at different time points in mice are repeated measures data. When the data is complete, a two-way repeated measures ANOVA with group × time was used; when there are missing values due to death or reaching the humanitarian endpoint, a mixed-effects model was used. Survival data were plotted using the Kaplan-Meier method, and the Log-rank (Mantel-Cox) test was used for overall inter-group comparisons; multiple comparison corrections were performed when pairwise comparisons were required.
[0140] Blood and tissue bacterial loads were log10 transformed before statistical analysis. Samples below the limit of detection (LOD) were processed according to pre-defined uniform rules and marked as LLOD in the graph. Kidney tissue damage scores are ordinal data, and Kruskal-Wallis test and Dunn multiple comparisons were used. P < 0.05 was considered statistically significant.
[0141] In the IR-61 dynamic tracing experiment, only one animal was involved in each time point of the conventional transurethral injection group. Therefore, this time series was only used as an exploratory and descriptive observation and no inferential statistical tests were performed. Independent biological replicates were set up in the pressurized perfusion 1 h group to confirm the early tissue distribution characteristics.
[0142] In summary, this application provides a method for constructing a mouse model of urinary sepsis. First, female C57BL / 6J mice are selected, and a specific concentration of urinary pathogenic Escherichia coli (UPEC CFT073) bacterial solution is continuously pumped into the bladder via a PE10 catheter at a constant flow rate (preferably 3 mL / h) and a total volume (preferably 1 mL), rather than being injected rapidly in one go. This process simulates the continuous high-pressure infection environment in clinical practice, significantly shortening the time it takes for bacteria to ascend from the bladder to the kidneys and enter the bloodstream, thus achieving minimally invasive and standardized operation.
[0143] Secondly, the model phenotype is regulated by precisely controlling key physical parameters. This invention specifies core parameters such as cannulation depth (7–9 mm), bacterial concentration (preferably 1 × 10⁸ / mL, adjustable to 10⁷–10⁹ / mL), and pumping duration (20 min). This parameterized design enables the model to stably reproduce the typical pathological features of urosepsis, namely "high bladder load – kidney involvement – bacterial entry into the bloodstream – dissemination to distant organs," while avoiding experimental failures due to arbitrary operation.
[0144] Finally, a high-bioburden systemic infection model was achieved without the need for laparotomy or implantation of foreign objects. This method utilizes pump-driven hydrodynamic effects to facilitate the rapid breach of the bladder barrier by bacteria, creating a severe sepsis model characterized by hypothermia, renal impairment, and high mortality, with the severity linearly adjustable through bacterial load.
[0145] The model characteristics of the transurethral bladder pressurized instillation method were verified through multiple levels, including fluid tracing, viable bacterial tissue distribution, body temperature, survival, renal tissue pathology, and renal function. IR-61 tracing showed that pump-driven continuous instillation could lead to earlier distribution of intrabladder fluid into the upper urinary tract and distant tissues. Viable bacterial experiments further demonstrated that the pressurized instillation group could simultaneously induce high bacterial loads in the bladder and kidneys, as well as bacterial dissemination to the blood and spleen, accompanied by hypothermia, renal tubular damage, and abnormal renal function. Compared with conventional transurethral retrograde injection, this method more easily induces systemic infection-related phenotypes in a shorter time. Compared with direct tail vein injection, this method preserves the initiation point and ascending infection process of the urinary tract infection. Furthermore, bacterial concentration gradient experiments indicated that the severity of the model is adjustable. Based on the experimental results, a CFT073 bacterial concentration of 1×10⁻⁶ was selected as the optimal concentration. 8 The standard modeling parameters were CFU / mL, total pump volume of 1 mL, flow rate of 3 mL / h, duration of action of 20 min, and insertion depth of 7–9 mm. Under the experimental conditions described in this application, this parameter combination resulted in a relatively stable phenotype of urinary tract infection progressing to systemic infection, while preserving a suitable window for subsequent observation.
[0146] In summary, this invention, through the combined technique of "transurethral catheterization + continuous pressure infusion via micro-pump," successfully solves the problem that traditional models cannot simultaneously ensure the authenticity of the source of infection and the speed of systemic response. It provides a method for constructing an animal model that is simple to operate, phenotypically stable, parameter-adjustable, and highly consistent with the pathogenesis of clinical urosepsis.
[0147] The mouse model of urosepsis constructed using the method provided in this application provides a basic model for subsequent screening or evaluation of drugs for the treatment of urosepsis.
Claims
1. A method for constructing a mouse model of urosepsis, characterized by: Includes the following steps: S1. Select mice and fix them in a supine position under anesthesia and warming conditions; S2. Prepare a bacterial suspension of pathogenic Escherichia coli in the urinary tract and adjust the bacterial suspension concentration; S3. Insert the catheter into the mouse bladder through the urethra, controlling the insertion depth to be 7-9 mm; S4. Place the bacterial solution prepared in S2 into a micro-injection pump, set the flow rate and total volume, and continuously pressurize the bladder to infuse the bacterial solution within a predetermined time. After infusion, stop the anesthesia and revive the mouse under warm conditions. After the mouse regains its righting reflex, return it to its rearing environment. The continuous pressurization refers to using a micro-injection pump to drive the liquid through a catheter into the bladder at a constant flow rate, forming a continuous infusion pressure and flow environment, which promotes the bacteria to develop upward along the urinary tract and enter the blood circulation.
2. The construction method of claim 1, wherein: The mice were 6-8 week old, SPF-grade female C57BL / 6J mice weighing 18-22 g.
3. The method of construction of claim 1, wherein: The urinary tract pathogenic Escherichia coli is UPECCFT073; the bacterial suspension is prepared by inoculating seed culture into LB medium, culturing to the logarithmic growth phase, collecting the bacterial cells by centrifugation, washing with sterile PBS, and resuspending.
4. The method of construction of claim 1, wherein: The bacterial solution concentration is adjusted in the range of 1 x 10 7 ~ 1 x 10 9 CFU / mL, and the severity of the model is adjusted by changing the bacterial solution concentration.
5. The method of construction of claim 4, wherein: The bacterial solution concentration is 1 x 10 8 CFU / mL.
6. The method of construction of claim 1, wherein: The catheter is made of PE10 polyethylene and has a cut length of approximately 10 mm.
7. The method of construction of claim 1, wherein: In step S3, before catheter insertion, air must be purged from the catheter and a sterile lubricant must be applied to the outer wall of the catheter for lubrication.
8. The method of construction of claim 1, wherein: In S3, the total pumping volume is 1 mL, the flow rate is 3 mL / h, and the duration is 20 min.
9. The method of construction of claim 1, wherein: After construction, the success of the model was evaluated by monitoring at least one of the following: changes in mouse body temperature, bacterial load in blood and distant organs (spleen, liver, heart), serum creatinine and urea nitrogen levels, and renal tissue pathological damage indicators.
10. The use of the mouse model of urosepsis constructed by the construction method according to any one of claims 1-9 in screening or evaluating drugs for the treatment of urosepsis.
